



RESEARCH NOTE

# Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables [version 1; peer review: 3 approved]

Daniel Strech <sup>1-3</sup>, Sören Sievers<sup>3</sup>, Stefanie Märtschenz <sup>4</sup>, Nico Riedel <sup>1</sup>, Susanne Wieschowski<sup>3</sup>, Jörg Meerpohl<sup>5</sup>, Holger Langhof <sup>1-3</sup>, Stephanie Müller-Ohtraun<sup>1</sup>, Ulrich Dirnagl <sup>1,2</sup>

<sup>1</sup>QUEST Center, Berlin Institute of Health (BIH), Berlin, Germany

<sup>2</sup>Charité - Universitätsmedizin Berlin, Berlin, Germany

<sup>3</sup>Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School, Hannover, Germany

<sup>4</sup>NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany

<sup>5</sup>Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany

**v1** **First published:** 29 Nov 2018, 7:1863 (<https://doi.org/10.12688/f1000research.17022.1>)  
**Latest published:** 29 Nov 2018, 7:1863 (<https://doi.org/10.12688/f1000research.17022.1>)

**Abstract**

**Background:** Several meta-research studies and benchmarking activities have assessed how comprehensively and timely, academic institutions and private companies publish their clinical studies. These current “clinical trial tracking” activities differ substantially in how they sample relevant studies, and how they follow up on their publication.

**Methods:** To allow informed policy and decision making on future publication assessment and benchmarking of institutions and companies, this paper outlines and discusses 10 variables that influence the tracking of timely publications. Tracking variables were initially selected by experts and by the authors through discussion. To validate the completeness of our set of variables, we conducted i) an explorative review of tracking studies and ii) an explorative tracking of registered clinical trials of three leading German university medical centres.

**Results:** We identified the following 10 relevant variables impacting the tracking of clinical studies: 1) responsibility for clinical studies, 2) type and characteristics of clinical studies, 3) status of clinical studies, 4) source for sampling, 5) timing of registration, 6) determination of completion date, 7) timeliness of dissemination, 8) format of dissemination, 9) source for tracking, and 10) inter-rater reliability. Based on the description of these tracking variables and their influence, we discuss which variables could serve in what ways as a standard assessment of “timely publication”.

**Conclusions:** To facilitate the tracking and consequent benchmarking of how often and how timely academic institutions and private companies publish clinical study results, we have two core recommendations. First, the improvement in the link between registration and publication, for example via institutional policies for academic institutions and private companies. Second,

**Open Peer Review**

**Referee Status:**

	Invited Referees		
	1	2	3
<b>version 1</b> published 29 Nov 2018	 report	 report	 report

- 1 **Christiane Pauli-Magnus** , University of Basel, Switzerland
- 2 **Shelly Pranić**, University of Split, Croatia
- 3 **Rabia Bashir** , Macquarie University, Australia

Any reports and responses or comments on the article can be found at the end of the article.

the comprehensive and transparent reporting of tracking studies according to the 10 variables presented in this paper.

### Keywords

clinical studies, trials, registries, follow-up, trial tracking, university medical centers, private companies

**Corresponding author:** Daniel Strech ([daniel.strech@charite.de](mailto:daniel.strech@charite.de))

**Author roles:** **Strech D:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Sievers S:** Conceptualization, Formal Analysis, Investigation, Writing – Review & Editing; **Märschenz S:** Conceptualization, Writing – Review & Editing; **Riedel N:** Conceptualization, Writing – Review & Editing; **Wieschowski S:** Conceptualization, Formal Analysis, Investigation, Writing – Review & Editing; **Meerpohl J:** Conceptualization, Writing – Review & Editing; **Langhof H:** Conceptualization, Formal Analysis, Investigation, Writing – Review & Editing; **Müller-Ohiraun S:** Conceptualization, Writing – Review & Editing; **Dirnagl U:** Conceptualization, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by Intramural funding of Charité – Universitätsmedizin Berlin, Hannover Medical School, and University of Freiburg.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2018 Strech D *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Strech D, Sievers S, Märschenz S *et al.* **Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables [version 1; peer review: 3 approved]** F1000Research 2018, 7:1863 (<https://doi.org/10.12688/f1000research.17022.1>)

**First published:** 29 Nov 2018, 7:1863 (<https://doi.org/10.12688/f1000research.17022.1>)

## List of abbreviations

CD, completion date; CENTRAL, Cochrane Central Register of Controlled Trials; CSR, clinical study reports; EU, European Union; FDA, Food and Drug Administration; FDAAA, Food and Drug Administration Amendments Act; GCP, Good Clinical Practice; ICH, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; ICMJE, International Committee of Medical Journal Editors; NCT, national clinical trial; PCD, primary completion date; UMC, University medical center

## Background

The results of clinical trials and observational studies form the basis of evidence-based decision making in health care, coverage decisions, the planning and funding of new research studies, ethics reviews, and research quality assessment<sup>1</sup>. Over the past three decades, several meta-research projects have demonstrated that the results of clinical studies are often not reported at all, or the reporting is incomplete, biased, or inconsistent with what was planned at the protocol stage<sup>2-5</sup>.

Recent studies have compared the proportion of trials/studies with published/disseminated results across academic institutions and for-profit companies. For instance, Chen *et al.* compared the publication rates of completed trials conducted by 51 academic medical centres across the US<sup>6</sup>. They found that overall, the results were published for 67% of 4,347 trials; however, the results of only 36% of trials were published within two years of study completion. They identified wide variation in the proportion of trials being published in a timely manner across the 51 medical centres. The **TrialsTracker** project, which started in 2016, automatically identifies completed trials on Clinicaltrials.gov, and links them with results from automated searches for published results to present data on publication rates at the individual study centre level (see **TrialsTracker**). In the newest version of **TrialsTracker**, approximately 65% of all applicable trials were found to be reported (accessed 21 March 2018). A third approach to this line of research is the “Good Pharma Scorecard”, which takes Food and Drug Administration (FDA)-approved drugs as a starting point, and provides benchmarks for transparency in industry-run clinical drug research and development<sup>7,8</sup>. In this initiative, the authors combined data from various sources (e.g., Clinicaltrials.gov, PubMed, Google Scholar) and different forms of results dissemination (summary reports, clinical study reports, peer-reviewed publications). This study revealed that of 505 trials relating to 31 drugs approved by the FDA in 2014, the results for a median of 68% of trials per drug were publicly available. The authors also found that in 233 of the 505 trials that were conducted with patients (in contrast to healthy participants), a median of 96% of trials, per drug, were publicly available.

The above-mentioned studies differed in many ways regarding their methods for sampling relevant clinical studies, and following up on their publication. What are the definition and operationalization of a “completed trial”? Should publication follow-up be applied only for prospectively registered trials,

or also for trials that were registered many months or years after the study started? What databases are searched for publications? What publication formats and contents count as a “publication”? What amount of time to publication is considered “timely”? Should only clinical trials or also observational studies be followed up on? Should only completed studies or also discontinued ones be followed up on? Different decisions on the various tracking variables and decisions on other methodologically relevant issues lead to different results for how academic institutions and for-profit companies perform overall and on comparative rankings or benchmarks.

The comprehensive and timely publication of clinical study results affects the reputation of academic institutions and private companies. Such data impact public trust and the willingness of foundations to fund research. To provide a basis for informed policy and decision making through publication assessment and benchmarking, this paper aims to identify and characterize the different variables affecting the results of tracking whether and how timely results from clinical studies are published.

## Methods

The selection of tracking variables presented in this paper was initially driven by expert knowledge and discussions within the group of authors. To validate the completeness of our set of tracking variables, we then conducted i) an explorative review of studies that followed up on the publication of clinical studies and ii) an explorative follow-up study of registered clinical trials of three leading German university medical centres (UMCs): Berlin, Freiburg, and Hannover.

The explorative review started with a set of eight follow-up studies that we were aware of<sup>6,8-14</sup>. All references of these (and the later-included) studies were evaluated for additional follow-up studies. Altogether, we identified 34 follow-up studies. All identified studies were read in full to extract reported methods for sampling and follow-up. The extracted content was checked for methodological details that our initial expert-driven set of tracking variables did not contain, and these were added to our set accordingly. The detailed results of this review of follow-up studies will be published elsewhere.

The methods for our explorative follow-up study have been published as a preregistered study protocol (Extended data<sup>15</sup>). We used an R script (see Software availability) to combine all relevant datasets from clinicaltrials.gov and search criteria needed to retrieve clinical trials from all 36 German UMCs and to extract their study characteristics. For each of the included studies, a results publication was searched independently by two researchers in a 3-step process in i) the registry, ii) in Pubmed, and iii) in Google Scholar. In the meantime, we conducted our study based on this protocol, evaluating all 36 German UMC as specified by the German Medical Faculty Association (MFT). The results of this comprehensive follow-up study will be published elsewhere. Our explorative follow-up study helped to further clarify how the tracking variables described in this paper influence the results of follow-up studies.

## Results

Based on the above-mentioned expert discussion, as well as the review of existing follow-up studies, and the insights from our explorative follow-up study of three German UMC, we were able to distinguish 10 variables influencing the design and results of follow-up studies of clinical studies. **Table 1** categorizes the 10 variables into two broad areas: “sampling of studies” and “follow-up of studies”.

Below, we describe the tracking variables, potential challenges in their operationalization, and their current influence on publication assessments. In the Discussion section, conceptual and normative issues for all 10 variables will be explored, and we will provide practical recommendations for future study tracking.

### 1. Responsible party for clinical studies

From a legal perspective, a specific university and its clinical study investigators are responsible for the dissemination of study results only if they are the “responsible party”, that is, if they are either the sponsor and/or the principal investigator. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP), for example, defines in section 1.53 that the sponsor is “an individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial”. The new European Union (EU) clinical trials regulation 536/2014, which is expected to come into force in 2019, also refers to the ICH GCP. According to that legal perspective, a specific university and its investigators who are “only” cooperating as a recruiting site are “not responsible” for whether and how timely the trial results are published. From an ethical perspective, however, physician investigators should only recruit participants for clinical trials that generate social value. Every recruiting physician investigator should therefore feel responsible for facilitating the timely publication of study results.

Several follow-up studies explicitly sampled clinical trials according to this legal definition of responsibility<sup>6</sup>. Other follow-up studies sampled all trials approved by local ethics committees, but did not further specify the issue of responsibility<sup>10,12</sup>. Our explorative study demonstrated that only one third of

trials conducted at the three German UMC are trials for which the university is the “legally” responsible party.

### 2. Type and characteristics of clinical studies

Clinical studies are broadly differentiated into *interventional* trials and *observational* studies, with different legal requirements. Therefore, studies following up on clinical studies for a specific university must decide whether to include both or only one study type or only subgroups, such as prospective cohort studies. ClinicalTrials.gov currently (21 July 2018) lists 221,251 interventional trials and 55,875 observational studies.

Most follow-up studies we reviewed focused on interventional trials. One exception is the study by Ross *et al.* that followed up on a sample of both types of clinical studies that were registered in ClinicalTrials.gov and found that the publication rate was 56% for interventional, placebo-controlled trials and 42% for observational studies<sup>11</sup>. In a recent study, Spelsberg *et al.* were able to follow up on a full sample of 558 observational post-marketing studies on adverse drug reactions<sup>16</sup>. They could not find any results reported for the 558 studies in the drug regulator’s public adverse drug reactions database. A peer-reviewed journal publication was found for five (1%) post-marketing studies<sup>16</sup>.

Another relevant characteristic of clinical studies is whether they are subject to *mandatory reporting* requirements. Several more recent follow-up studies excluded all trials that do not fall within the mandatory reporting rules according to the Food and Drug Administration Amendments Act (FDAAA) 801<sup>7,11,14,17</sup>.

### 3. Status of clinical studies

Most follow-up studies focus on the analysis of how timely *completed* studies are published, e.g.,<sup>11,17,18</sup>. These follow-up studies therefore must exclude all *terminated*, *discontinued*, and *withdrawn* trials. Knowledge, however, is also gained from discontinued trials that, for example, report recruitment barriers or unanticipated adverse effects. A follow-up study by Pica *et al.* explicitly included all clinical trials, irrespective of whether they were completed, terminated, withdrawn, or suspended<sup>13</sup>. Anderson *et al.* also included both completed and terminated studies<sup>14</sup>. Others further specified the exclusion of non-completed studies. Miller *et al.*, for example, stated that they excluded

**Table 1. Sampling and tracking variables and related questions.**

Sampling	Tracking
<p><b>1. Responsible party for clinical studies:</b> Should the sampling refer to the legal or ethical perspective on “responsible party”?</p>	<p><b>6. Determination of completion date:</b> How should “trial completion” be defined</p>
<p><b>2. Type and characteristics of clinical studies:</b> What study type (clinical trial, observational) with what further study characteristics to follow up?</p>	<p><b>7. Timeliness of dissemination:</b> What time frames between end of trial and dissemination are specified for the follow-up?</p>
<p><b>3. Status of clinical studies:</b> Should only completed studies or also discontinued, terminated trials be followed up on?</p>	<p><b>8. Format of publication/dissemination:</b> What publication formats and contents should count as results publication?</p>
<p><b>4. Sources for sampling:</b> What source (registry, IRB archives etc.) should be used for identifying institution-specific clinical studies?</p>	<p><b>9. Sources for tracking:</b> Where (registry, database, web engines etc.) and how should publications be searched for?</p>
<p><b>5. Timing of registration:</b> How should retrospectively registered studies be dealt with?</p>	<p><b>10. Inter-rater reliability:</b> How are interpretive judgments and inter-rater differences dealt with?</p>

any trials that were terminated without participant enrolment<sup>7</sup>, but they do not explicitly state how they addressed other types of terminated, withdrawn, or suspended trials. Kasenda *et al.* showed that for 1,017 clinical trials approved at one of six institutional review boards (IRBs) in Germany, Switzerland and Canada, 25% were discontinued<sup>12</sup>. Discontinued trials were more likely to remain unpublished than completed trials (55% vs 34%).

#### 4. Source for sampling

IRB archives should be the most sensitive and least biased source for sampling all clinical studies conducted at one specific university, at least in countries where ethics reviews of clinical studies became mandatory sometime after the 1975 Tokyo revision of the Declaration of Helsinki<sup>19</sup>. The previously mentioned study by Kasenda *et al.*, for example, found that 10 years after the IRB approval of 1,017 clinical trials, the results of 56% (n=567) were published as a full journal article<sup>12</sup>.

In practice, however, most newer studies following up on clinical trials refer to public registries, as this is more convenient and practicable. Registries, however, rarely include all clinical studies conducted at any given university. The prospective registration of clinical trials in a public registry became legally binding under FDAAA 801 in the USA for all phase II/III trials in 2007. Another strong incentive to register clinical trials was the International Committee of Medical Journal Editors (ICMJE) policy issued in 2015, which recommends that all medical journals require prospective registration as a condition of consideration for publication<sup>20</sup>. In the EU, prospective registration for clinical trials in the public EU Clinical Trials Database will become a legal requirement with EU regulation 536/2014 (Article 67). However, the same Article 67 still allows certain pieces of information not to be published, i.e. also recognizing the “legitimate economic interests” of sponsors. All clinical studies that do not fall under these laws (observational studies, trials on psychotherapy, surgery studies) can nevertheless be registered, even retrospectively. Van den Bogert *et al.* found publication rates of 75% for prospectively registered IRB-approved clinical trials and 48% for non-registered trials<sup>21</sup>.

#### 5. Timing of registration

The inclusion of all registered trials by studies following up on the publication of results might overestimate publication rates for another reason. Even trials with mandatory registration are sometimes registered after the sponsor plans to publish the results, and then realizes that this requires registration. Although the above-mentioned ICMJE policy explicitly refers to prospective registration, many journals also allow retrospective registration<sup>22,23</sup>.

How to determine the cut-off between prospective and retrospective registration is complicated by two points. First, legal obligations for registration allow a time window. The FDAAA 801, for example, requires trial registration within 21 days after the enrolment of the first participant. Second, several “timings” for registration can be distinguished. The ISRCTN registry, for example, reports both the date that researchers submitted their request for registration and the date that trial registration was completed.

Recent follow-up studies have differed in how they deal with retrospectively registered trials and how they define “retrospective”. Pica *et al.*, for example, excluded all trials that were registered more than 60 days after the study started<sup>13</sup>. Others, such as Chen *et al.* and TrialsTracker, did not exclude retrospectively registered trials at all and did not allow for subgroup analyses<sup>6,24</sup>.

In our explorative follow-up study, we found that the proportion of trials with published results was 68% for all prospectively registered trials, 73% for trials registered more than 60 days after the trial started, and 82% for trials registered after study completion. We also found 16 trials registered after the date of the first results publication, which of course have a 100% publication rate.

#### 6. Determination of completion date

One can broadly distinguish three ways to determine the completion date of an interventional trial: A) the “primary completion date” (PCD), which, according to ClinicalTrials.gov, is the “date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure”, B) the later “completion date” (CD), which is defined as the date of the last participant’s last visit to collect final data, and thus also includes secondary outcome measures and adverse events, or C) the “estimated” study completion date, which is the study completion date expected by the researchers. According to the ClinicalTrials.gov glossary, the “estimated” date is perceived in the same way as the CD.

At present, follow-up studies using registries are heterogeneous with regard to the CD definition to which they refer. Some refer to the PCD<sup>14,18</sup>, some refer to the CD<sup>11</sup>, and some do not specify<sup>25</sup>. A follow-up study that sampled clinical study protocols archived at IRBs regarded a study as completed if the data collection was terminated or if the study results were published<sup>10</sup>.

In our pilot follow-up study, we found, unsurprisingly, that the proportion of published trials is higher for all three German UMC 24 months after the CD (35% of trials published) than 24 months after the PCD (28% published).

#### 7. Timeliness of publication

Of course, the proportion of published studies also varies considerably with regard to what one accepts as “timely”. Both the FDA and EU legal frameworks allow 12 months for the publication of “summary results”, which form part of the respective registry entries. The FDAAA has mandated results reporting since 2008<sup>26</sup>. The EU Commission introduced similar requirements in 2014 but is still facing implementation barriers<sup>27</sup>. However, no official standards exist for how timely more detailed and contextualized results should be published in peer-reviewed journals.

Ongoing and past follow-up studies have dealt differently with how and where to set adequate time frames. TrialsTracker reports the proportion of trials for each sponsor published within 24 months after the PCD<sup>9,24</sup>. Ross *et al.* reported the publication rates for a timeframe of 30 months after the CD. Chen *et al.* focused their results reporting on 24 months after the PCD but

also illustrated how the publication ratio changed with alternative timeframes<sup>6</sup>. Miller *et al.* compared the publication ratio at FDA approval, and 3 months and 6 months post-approval<sup>8</sup>. Many other follow-up studies have assessed the all-time publication ratio, often allowing more than 10 years between the completion and publication of the trial<sup>10,12</sup>.

In our pilot study with three German UMC, we found publication rates (including summary results) of 16% for 12 months after the CD, 35% for 24 months after the CD, and 71% for all-time follow-up.

## 8. Format of publication/dissemination

What should count as a relevant publication or other dissemination format? Peer-reviewed publications are the typical dissemination format and were accordingly accepted by almost all of the above-mentioned follow-up studies. Another newer, but increasingly accepted, dissemination format is that of the previously mentioned summary results<sup>6,9</sup>. Miller *et al.* further included clinical study reports (CSRs)<sup>8</sup>. Other formats such as theses, conference proceedings, books, or data uploaded on data-sharing platforms might also reveal important and sufficient information on trial results. The 34 follow-up studies we are aware of did not include any of the latter publication formats in their searches.

Irrespective of the dissemination format, one might count only those result publications that report the essential information needed. Guidance exists on the essential content to be included in summary results (see [ClinicalTrials.gov](https://www.clinicaltrials.gov)<sup>28</sup> definitions), journal publications<sup>29</sup>, and CSRs<sup>30</sup>. However, appraising each identified publication for its comprehensiveness and appropriateness requires considerable time. Some follow-up studies invested this time. Kasenda *et al.*, for example, checked all full texts of retrieved publications and demonstrated that they often do not report on all predefined outcomes or deviate in other ways from registered information on the study design<sup>31</sup>.

## 9. Sources for tracking

Time to publication also strongly depends on where publications are sought. A first obvious search can be performed on the registry itself. The ClinicalTrials.gov database highlights for each trial the “first results received”, if available. However, the “first results received” only illustrate when summary results for the trial were reported. The registry entry for each trial further automatically indexes all publications listed in PubMed that mention the trial-specific NCT identifier in the abstract (see [NIH page of registry numbers](https://www.nih.gov))<sup>32</sup>. Furthermore, ClinicalTrials.gov allows sponsors and principal investigators to manually index publications for registered trials.

Another obvious search strategy is to search PubMed for the NCT number. As the automatic indexing at ClinicalTrials.gov does not work in all cases, this approach might reveal additional result publications. In our explorative follow-up study of German UMC, we identified an additional 3% of result publications via this approach. Chen *et al.* and TrialsTracker also checked for NCT identifiers in PubMed<sup>6,24</sup>.

Further search strategies become more time intensive and require more interpretive judgements. Bluemle *et al.* searched the Cochrane Central Register of Controlled Trials (CENTRAL)<sup>10</sup>. They contacted the applicants of all included protocols by personal letter. For each submitted protocol, they asked individually about the current project status, the verification of already-identified publications, and references of additional publications they may have missed. Their literature searches identified 138 full publications, and the survey identified an additional 72. However, Bluemle *et al.* did not report how much these additional publications changed the overall publication rate, which turned out to be 48%<sup>10</sup>.

None of the 34 follow-up studies we are aware of searched publications for trials in general search engines such as Google, Bing, or Yahoo. In our follow-up of trials from three German UMC, we identified result publications for 48% of all trials by searching summary results and indexed publications at the respective registry entries, combined with PubMed searches for NCT identifiers. However, additional manual searches in Google by two independent searchers yielded result publications for another 27% of trials. The manual search, therefore, increased the overall proportion of result publications to 75% for the three academic institutions.

Finally, some private drug and medical device companies operate company-specific databases that might list publications from completed trials. In response to results from TrialsTracker, a blogger, Adam Jacobs, argued that the 45% of trials that TrialsTracker found to be undisclosed shrink to 21% if one searches in these company-specific databases (see [The Stats Guy blog](https://www.thestatsguy.com))<sup>33</sup>. However, each of these company-owned databases functions in a different way, and many companies do not publish such databases.

## 10. Inter-rater reliability

Expertise, ideally from more than one rater, is required to determine whether a publication matches a specific trial, and can thus be considered ‘published’. This certainly applies if manual searches in databases or internet search engines are added to automated registry and database checks. In Kasenda *et al.*, for example, two investigators working independently, and in duplicate determined whether identified publications matched the corresponding protocol<sup>12</sup>.

As we also applied manual searches in our explorative follow-up study, we had at least two researchers independently search for publications of registered trials. Although all researchers had a background in systematic review methodology and were trained in identifying result publications for clinical trials, we faced high inter-rater differences. For 16% of all trials, a publication was found by only one person, and for 10% of all trials, two different publications were found.

## Discussion

In this paper, we identified and characterized 10 variables influencing the tracking of whether and how timely clinical

studies from academic institutions and private companies are disseminated. We further demonstrated the current opportunities and challenges of using these variables in tracking studies. Some of these variables need further conceptual and normative clarification.

**Responsible party for clinical studies:** First, we see the need to revisit our understanding of who is “responsible” for the timely (and unbiased) publication of trial results. All physicians functioning as investigators and their universities should not feel responsible only for trials where they are the legally defined “responsible party”. Investigators (both principal and co-investigators) and the hosting academic institutions are ethically obliged to proactively force the timely publication of all trials that recruited “their” patients, even if they only recruited as a cooperating partner. The risks and burdens for patients participating in clinical trials are justifiable only if the study generates social value in terms of knowledge gains. Therefore, the timely and unbiased publication of trial results is to be understood as a basic promise each physician investigator gives to participants recruited for a specific study.

Current efforts to benchmark universities should consider the current legal and ethical perspectives on “responsibility” for timely publication. This requires following up on *all* clinical studies that recruit patients from a given UMC, irrespective of whether the university was the sponsor/principal investigator or only a cooperating partner/facility. Data on the publication ratios of the two samples could be reported separately.

**Types and characteristics of clinical studies:** Observational clinical studies are less regulated than interventional drug and device trials, and they do not face mandatory registration or reporting policies. From an ethical and economic perspective, however, those conducting observational studies have the same duties to increase value and reduce waste in biomedical research. For pragmatic reasons, follow-up studies currently focus on clinical studies that face mandatory registration and reporting, but future activities should also aim to shed more light on the registration and publication practices for other types of clinical studies.

**Status of clinical studies:** Reporting on the results or relevant barriers of discontinued, withdrawn, or early terminated studies is governed by the same ethical guidelines as completed clinical studies. Reporting does not necessarily require peer-reviewed publications but could also include reporting at registry websites and data-sharing platforms. The reporting of discontinued trials is a relevant measure to benchmark universities’ and companies’ contributions to increasing value and reducing waste in research. The extent of trial discontinuation itself, however, does not serve as an appropriate measure for benchmarking activities. Academic institutions or companies conducting many complex or high-risk trials where discontinuation might be more probable than in simple trial designs should not be censured or discouraged. Furthermore, stigmatizing the discontinuation of trials might result in the inappropriate continuation of trials.

**Sources for sampling:** As long as study registration is not mandatory for all clinical studies, follow-up studies sampling

at the registry level will most likely overestimate the true proportion of published clinical studies. To better understand the reporting performance of individual academic institutions and companies for non-registered clinical studies, follow-up studies must sample at the IRB level. Another way to improve opportunities to evaluate the reporting of, for example, observational studies would be legal or institutional policies requiring the prospective registration of all clinical studies.

**Timing of registration:** Little is known about how much the timing of registration affects the likelihood of results publication of clinical studies. Our above-reported results from a pilot study indicate a higher proportion of results publication in retrospectively registered trials. Follow-up studies interested in benchmarking the timely publication of trial results for universities or companies, therefore, should either focus on samples of prospectively registered trials to avoid bias or at least report the subgroup results for all prospectively and retrospectively registered trials.

**Determination of completion date:** Another normative and policy-oriented question is whether the appropriate definition of “completion” should refer to the PCD or the CD (see definitions above). Should certain trials be labeled as “not timely published” with reference to a 24-month time window after the PCD, even if they published the primary and secondary outcomes within 24 months after the CD? In line with European law (536/2014 Art 37.4), we propose taking the CD as the start date when following up on the reporting of summary results and peer-reviewed publications.

**Timeliness of dissemination:** We need a standard for what counts as “timely” publication. Several laws require the publication of summary results for certain types of studies within 12 months after the PCD (USA) or the CD (EU). Many other national laws, however, have no requirement in this regard. What should be seen as an ethically justifiable time to appropriately disseminate trial results via peer-reviewed publications or other dissemination formats? We propose 24 months after the CD as a potential normative standard for “timely publication” of peer-reviewed publications or similarly comprehensive and contextualized dissemination formats. Even for busy researchers, this 24-month period should allow enough time to publish. Publishing peer-reviewed results more than 24 months after the CD is, of course, better than not reporting them at all, but it should not be labeled as being “timely”. According to recent follow-up studies, less than 15% of all trials reported summary results within 12 months after the PCD<sup>14</sup>, and less than 30% produced peer-reviewed publications within 24 months after the CD<sup>6</sup>.

**Format of publication/dissemination:** Another complex issue is what types of publication or dissemination of trial results one should accept as appropriate. Most follow-up studies currently search for published summary results and/or peer-reviewed publications. But what about trial results provided via data-sharing platforms only or by industry-owned databases? Recent follow-up studies have demonstrated that accepting other publication formats, such as CSRs, yields higher publication rates<sup>8</sup>. It is

problematic, however, that these publications are not more easily accessible. Sponsors or investigators should directly link all publications, irrespective of their publication format, to the relevant registry entry of the respective trial. Registries can thus become the one-stop shop for clinical trial stakeholders (e.g., physicians, patients, systematic review and clinical guideline groups, meta-research, oversight).

**Sources for tracking:** As indicated above, at present, the addition of manual searches for publications in internet search engines and for CSRs in industry-owned trial databases yields a much higher number of result publications. Follow-up studies should explicitly acknowledge these limitations if they apply less extensive searches. From a normative perspective, however, these limitations and complexities in searching for result publications are themselves a problem. The above-mentioned registry entry as a one-stop shop for clinical trial results could solve this problem. Academic institutions and private companies should develop policies and incentives for linking result publications with the registry entry of the relevant trial.

**Inter-rater reliability:** Our finding that even experts trained in searching for clinical trials relatively often found different publications for the same trials once again speaks in favour of the one-stop shop approach.

Our study has the following limitations. First, although we reviewed more than 30 follow-up studies, and engaged in following up on clinical trials from German UMC, we might either have missed important tracking variables, or framed the 10 outlined tracking variables in a way that underplays certain aspects that deserve more attention. Second, in our outlines and the discussion of the 10 tracking variables, we only gave examples of how they are currently operationalized in follow-up studies. We will publish more detailed descriptions of the existing body of follow-up studies elsewhere.

### Recommendations

First, registration and publication activities for specific trials should be better linked — from publication to registry entry and from registry entry to publication. This applies not only to peer-reviewed papers including the NCT but also to CSRs, PhD theses, and other formats for results publication. Consequently, registry entries for clinical studies should become a one-stop shop for clinical study stakeholders. If successful and broadly established, the threaded publications initiative might become an even more appropriate one-stop shop in this regard<sup>34,35</sup>.

Second, to reach this goal, academic institutions and private companies should develop policies and incentives to further improve i) the registration of all their clinical studies, ii) the timely publication of all their completed and discontinued studies, and iii) the effective linkage of registry entries and their respective publications.

Third, future follow-up and tracking studies, as well as consequent rankings/benchmarking for academic institutions and private companies, should be transparent on how they specified

the 10 tracking variables outlined in this paper and why they did so with regard to their follow-up objectives.

Recent efforts at more systematic, comprehensive, and sustained follow-up/tracking activities around the timely publication of clinical studies in combination with recent announcements from leading funders to require and evaluate result publication suggest an intensified public interest in the topic. Therefore, ranking and benchmarking academic institutions and private companies according to their registration and publication efforts seems to be a logical consequence. We hope that our clarification of relevant tracking variables will help make these new assessment activities more valid, effective, and efficient from the start.

### Software availability

The R script used to as part of this study is available from Open Science Framework <https://doi.org/10.17605/OSF.IO/FH426><sup>15</sup>

Licence: MIT License

### Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Data generated in the pilot study as well as the subsequent follow-up study of all German UMCs will be published in a separate publication that will be linked in the Open Science Framework registration of the project.

OSF: Dataset 1: IntoValue. <https://doi.org/10.17605/OSF.IO/FH426><sup>15</sup>

The data is available under a CC0 1.0 Licence

### Extended data

The methods for our explorative follow-up study have been published as a preregistered study protocol, available from Open Science Framework.

OSF: Extended data: IntoValue. <https://doi.org/10.17605/OSF.IO/FH426><sup>15</sup>

Available under a CC0 1.0 licence

---

### Grant information

This study was supported by intramural funding of Charité – Universitätsmedizin Berlin, Hannover Medical School, and University of Freiburg.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

### Acknowledgements

We thank the members of the IntoValue team, namely, Bob Siegerink, Katharina Kunzweiler, Christopher Schürmann, Hannes Kahrass, and Sean Kelley, for their contribution to the design and conduct of the pilot study with three German UMC.



## References

1. Macleod MR, Michie S, Roberts I, *et al.*: **Biomedical research: increasing value, reducing waste.** *Lancet.* 2014; **383**(9912): 101–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Chan AW, Song F, Vickers A, *et al.*: **Increasing value and reducing waste: addressing inaccessible research.** *Lancet.* 2014; **383**(9913): 257–66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Song F, Parekh S, Hooper L, *et al.*: **Dissemination and publication of research findings: an updated review of related biases.** *Health Technol Assess.* 2010; **14**(8): iii, ix–xi, 1–193.  
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Dickersin K, Min YI, Meinert CL: **Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards.** *JAMA.* 1992; **267**(3): 374–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Easterbrook PJ, Berlin JA, Gopalan R, *et al.*: **Publication bias in clinical research.** *Lancet.* 1991; **337**(8746): 867–72.  
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Chen R, Desai NR, Ross JS, *et al.*: **Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers.** *BMJ.* 2016; **352**: i637.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Miller JE, Korn D, Ross JS: **Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.** *BMJ Open.* 2015; **5**(11): e009758.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Miller JE, Wilenzick M, Ritcey N, *et al.*: **Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.** *BMJ Open.* 2017; **7**(12): e017917.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. FDAAA Trialtracker: **EBM DataLab.** 2018.  
[Reference Source](#)
10. Blumle A, Meerpohl JJ, Schumacher M, *et al.*: **Fate of clinical research studies after ethical approval—follow-up of study protocols until publication.** *PLoS One.* 2014; **9**(2): e87184.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Ross JS, Mulvey GK, Hines EM, *et al.*: **Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis.** *PLoS Med.* 2009; **6**(9): e1000144.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Kasenda B, von Elm E, You J, *et al.*: **Prevalence, characteristics, and publication of discontinued randomized trials.** *JAMA.* 2014; **311**(10): 1045–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Pica N, Bourgeois F: **Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children.** *Pediatrics.* 2016; **138**(3): pii: e20160223.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Anderson ML, Chiswell K, Peterson ED, *et al.*: **Compliance with results reporting at ClinicalTrials.gov.** *N Engl J Med.* 2015; **372**(11): 1031–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. **Protocol for IntoValue at OSF.**  
<http://www.doi.org/10.17605/OSF.IO/FH426>
16. Spelsberg A, Prugger C, Doshi P, *et al.*: **Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.** *BMJ.* 2017; **356**: j337.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Prayle AP, Hurley MN, Smyth AR: **Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.** *BMJ.* 2012; **344**: d7373.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Gordon D, Taddai-Peters W, Mascette A, *et al.*: **Publication of trials funded by the National Heart, Lung, and Blood Institute.** *N Engl J Med.* 2013; **369**(20): 1926–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. World Medical Association: **Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.** Fortaleza, 2013.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. De Angelis C, Drazen JM, Frizelle FA, *et al.*: **Clinical trial registration: a statement from the International Committee of Medical Journal Editors.** *N Engl J Med.* 2004; **351**(12): 1250–1.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. van den Bogert CA, Souverein PC, Brekelmans CT, *et al.*: **Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.** *PLoS One.* 2016; **11**(12): e0167709.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Harriman SL, Patel J: **When are clinical trials registered? An analysis of prospective versus retrospective registration.** *Trials.* 2016; **17**: 187.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Loder E, Loder S, Cook S: **Characteristics and publication fate of unregistered and retrospectively registered clinical trials submitted to *The BMJ* over 4 years.** *BMJ Open.* 2018; **8**(2): e020037.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Powell-Smith A, Goldacre B: **The TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions [version 1; referees: 2 approved].** *F1000Res.* 2016; **5**: 2629.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Shamlivan T, Kane RL: **Clinical research involving children: registration, completeness, and publication.** *Pediatrics.* 2012; **129**(5): e1291–300.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Tse T, Williams RJ, Zarin DA: **Reporting “basic results” in ClinicalTrials.gov.** *Chest.* 2009; **136**(1): 295–303.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. European Commission (2012/C 302/03): **Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006.** 2012.  
[Reference Source](#)
28. US National Library of Medicine: **ClinicalTrials.gov Results Data Element Definitions for Interventional and Observational Studies.** 2018.  
[Reference Source](#)
29. Schulz KF, Altman DG, Moher D, *et al.*: **CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.** *PLoS Med.* 2010; **7**(3): e1000251.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. EMA: **ICH Topic E 3: Structure and Content of Clinical Study Reports.** 1996.  
[Reference Source](#)
31. Kasenda B, Schandelmaier S, Sun X, *et al.*: **Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications.** *BMJ.* 2014; **349**: g4539.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. NIH: **Clinical Trial Registry Numbers in MEDLINE/PubMed Records.**  
[Reference Source](#)
33. Jacobs A: **The trials tracker and post-truth politics.** 2016.  
[Reference Source](#)
34. Altman DG, Furberg CD, Grimshaw JM, *et al.*: **Linked publications from a single trial: a thread of evidence.** *Trials.* 2014; **15**: 369.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Chalmers I, Altman DG: **How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing.** *Lancet.* 1999; **353**(9151): 490–3.  
[PubMed Abstract](#) | [Publisher Full Text](#)

# Open Peer Review

Current Referee Status:



Version 1

Referee Report 13 May 2019

<https://doi.org/10.5256/f1000research.18611.r47054>



**Rabia Bashir** 

Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia

This manuscript presents a study based on 10 variables influencing the tracking of clinical studies and timely dissemination of their published results. The selection of these tracking variables is driven by expert knowledge and discussion among authors. To validate the completeness of these tracking variables, the authors used a sample of 34 studies that followed up on the publication of registered clinical trials of three leading German university medical centres (UMC). Based on a review of these studies, the authors make several recommendations. These include strengthening links between registry entry and publications and coordination among academic institutions and private companies to ensure the registration of clinical studies.

The study addresses an interesting topic by listing a range of factors that influence the tracking and dissemination of clinical evidence. The paper is generally well written and structured. It would be interesting to see the detailed results; which the authors are aiming to publish elsewhere.

I liked the study idea and agree with most of the conclusions that the authors have drawn and the recommendations that the authors have made. I agree that observational studies need to be registered because they can be used to influence policy and provide basis for clinical decision making. Also, the finding that up to 75% of published results can be linked to registry entries by adding manual searches support the conclusions made in another systematic review (Bashir *et al.*, 2017<sup>1</sup>).

However, I have a few minor suggestions for strengthening the research:

- Studies are likely to be a biased representation because they were selected from leading German university medical centres for selecting the studies. They find that 35% are published at 24 months after completion date. It is not clear how these results might generalise so it is important that the conclusions do not over-generalise.
- The standard for “timely publication” was defined to be 24 months after the completion date. Using this as a standard for what counts as publication is arbitrary and while there are some details on mandates and policies the standard could have been better justified by the authors. A possible alternative might be to consider a model that estimates the median time to publication using a range of characteristics as factors, and avoid needing to choose a specific amount of time to judge what is timely and what is not.

- I agree with the authors' recommendation that academic institutions and private companies need to play a role to improve the registration of clinical trials and their links with published results. However, journals are also often responsible for ensuring that trial registration information is provided. First, by following ICMJE guidelines on prospective registration. Second, they can ensure the identifier is included in the abstract and metadata they send to bibliographic databases. This will help to ensure that journals do not publish any clinical trials where trial identifier is not included in paper by authors or trial investigators.
- The manuscript can get benefit from these references: Trinquart *et al.* (2018<sup>2</sup>) and Bashir *et al.* (2017<sup>1</sup>).

### References

1. Bashir R, Bourgeois F, Dunn A: A systematic review of the processes used to link clinical trial registrations to their published results. *Systematic Reviews*. 2017; **6** (1). [Publisher Full Text](#)
2. Trinquart L, Dunn A, Bourgeois F: Registration of published randomized trials: a systematic review and meta-analysis. *BMC Medicine*. 2018; **16** (1). [Publisher Full Text](#)

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

No

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Clinical Research Informatics and Software Engineering

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 10 May 2019

<https://doi.org/10.5256/f1000research.18611.r47315>



**Shelly Pranić**

Department of Public Health, School of Medicine, University of Split, Split, Croatia

I agree with Reviewer 1 in that this study by Strech *et al.* provides a comprehensive list of variables to take into account when tracking the publication of clinical trial data. Now, with their applicable checklist, researchers can fine-tune their tracking of the data from trials. The paper is well-written, cites relevant literature, and describes the chosen variables well; however, since a part of this research involves a qualitative portion, it would be informative to describe the 'explorative review' clearer. Additionally, point 7 could be expanded. Please find comments below for your review, thank you.

**Methods:**

1. Regarding the 'explorative review,' it would be interesting to know what was the initial list of tracking variables compiled by the authors before arriving at 10. The cited methodology on OSF does not describe this step. It is unclear how the authors voted or decided on the tracking variables. This explorative review is qualitative in nature and the authors should describe the way they chose the variables with greater clarity so that this part of the study could be replicated by other researchers.

**Discussion:**

1. Timeliness of the publication: I agree that researchers have limited time to publish, but as these tracking variables are also intended for assessing timeliness of companies' publications (including pharmaceuticals), the authors could also mention that there could be embargoes set forth by pharmaceutical industry officials and how embargoes could play a role in the timeliness of the publication of trial data irrespective of authors' available time to publish. I think this is a point worth mentioning in this section of the Discussion.

**References**

1. Pauli-Magnus C: Referee Report For: Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables [version 1]. *F1000Research*. 2019; **7** (1863).

[Reference Source](#)

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Clinical trial reporting, public health, research assessment, and peer review.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 21 February 2019

<https://doi.org/10.5256/f1000research.18611.r44341>



**Christiane Pauli-Magnus** 

Department of Clinical Research, University of Basel, Basel, Switzerland

The paper by Strech *et al.* on tracking the timely dissemination and publication of clinical study results addresses a very relevant topic especially in academic clinical research. Since the metrics on published trials per institution/organisation are easily available through public databases such as the 'trialstracker' project, the ethical and scientific dimension of incomplete publication of clinical study results is gaining increasing public attention. Consequently, universities and university hospitals are asked to define measures on how to track and improve publication rates.

Based on a literature review and an exploratory tracking of registered clinical trials conducted at three leading German university medical centres, the authors examine and discuss ten different tracking variables for clinical study publications. They finally come up with a set of recommendations on how academic institutions and private companies could increase trial publication.

In my opinion, the work is clearly presented and cites the relevant literature. It uses appropriate methods and gives sufficient detail to be replicated by others. However, the detailed results of the review of follow-up studies is not given in the paper as it is planned to be published elsewhere.

While I agree with the overall methodological approach and the results, I do not agree with the entire conclusion:

1. Responsible party for clinical studies: according to ICH-GCP, the overall responsibility for a clinical study including the publication lies with the study sponsor. Institutional follow-up on studies where the overall responsibility is with a third party (e.g. with a commercial sponsor or another academic institution in case of academic multicentre trials) will increase the bureaucratic burden of the institution without increasing publication rates. I would rather enforce that academic institutions establish policies to follow-up on the trials where they have sponsor-investigator responsibilities.
2. Source of sampling: Sampling studies at the IRB level will not resolve the problem of incomplete/inaccurate sampling. For instance, a positive IRB vote does not necessarily mean that a study has been started and IRB data on study discontinuation are probably as incomplete as registration data in public registries. Furthermore, depending on national legislation, IRB data are not publically accessible. I therefore would strongly support to rather invest in institutional policies that support mandatory study registration in a public study registry.

- 3. Timeliness of dissemination: I disagree that a 24-month period after CD should be enough time to publish even for busy investigators. This might be the case for studies, which are rapidly accepted for publication. In the case of studies with e.g. negative results, or results from discontinued/incomplete studies, substantial delay can derive from submission and resubmission processes. The clear definition of 'timely' therefore needs a publication platform that is equally accessible to all study sponsors, independent of study 'success'.

On the other hand, I strongly support the overall recommendations that registration and publications activities should be better linked. I also think that registration and publication should be tracked for all prospective interventional AND observational clinical research and should include publication tracking for discontinued/incomplete studies. I like the idea that academic institutions should develop policies and incentives to improve registration and publication. By supporting clinical researchers during registration as part of a mandatory policy established at the University Hospital Basel in 2018, we could double the number of studies registered at clinicaltrials.gov within one year. These are relatively easy measures with substantial local impact. However, on a national/international scale I am convinced that only a multi-stakeholder approach, including e.g. academic institutions, funders, IRBs and publishers will improve traceability and publication of study results.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

No

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Methodological Research/ Research on Research in the Areas of clinical Research Quality (e.g. Monitoring, Trial Registration)

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**